litlas
Log inCreate account

Stan B. Kaye

Active 1989–2022

90
Papers
26,812
Citations
78
h-index
90
i10-index

Citations

Citations per year for Stan B. Kaye1896: 1 citations1991: 4 citations1992: 5 citations1993: 17 citations1994: 14 citations1995: 19 citations1996: 28 citations1997: 19 citations1998: 35 citations1999: 31 citations2000: 39 citations2001: 37 citations2002: 30 citations2003: 71 citations2004: 94 citations2005: 102 citations2006: 112 citations2007: 140 citations2008: 154 citations2009: 217 citations2010: 357 citations2011: 396 citations2012: 381 citations2013: 363 citations2014: 365 citations2015: 352 citations2016: 340 citations2017: 325 citations2018: 265 citations2019: 830 citations2020: 810 citations2021: 695 citations2022: 534 citations2023: 317 citations2024: 467 citations2025: 205 citations2026: 2 citations1897–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,066 citing papers, 27.2% of this breakdownUnited Kingdom: 1,160 citing papers, 10.3% of this breakdownChina: 1,046 citing papers, 9.3% of this breakdownItaly: 562 citing papers, 5% of this breakdownGermany: 484 citing papers, 4.3% of this breakdownFrance: 463 citing papers, 4.1% of this breakdownCanada: 439 citing papers, 3.9% of this breakdownNetherlands: 359 citing papers, 3.2% of this breakdownSpain: 337 citing papers, 3% of this breakdownAustralia: 334 citing papers, 2.9% of this breakdownJapan: 267 citing papers, 2.4% of this breakdownSwitzerland: 211 citing papers, 1.9% of this breakdown
0%27.2%Other 22.5%

Institutions

Fields

  • Medicine59.7%
  • Biochemistry, Genetics and Molecular Biology30.7%
  • Materials Science3.1%
  • Immunology and Microbiology1.6%
  • Engineering1%
  • Chemistry0.8%
  • Other3.1%

Topics

  • PARP inhibition in cancer therapy8%
  • Ovarian cancer diagnosis and treatment5.4%
  • DNA Repair Mechanisms4.3%
  • Cancer Genomics and Diagnostics2.7%
  • Prostate Cancer Treatment and Research2.2%
  • BRCA gene mutations in cancer2.2%
  • Other75.2%

Coauthors

All papers

Open in search
  1. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Authors: Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono - New England Journal of Medicine 2009 cited by 3,632

  2. A decade of clinical development of PARP inhibitors in perspective

    Authors: J. Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono - Annals of Oncology 2019 cited by 730

  3. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

    Authors: Emma Kipps, David S.P. Tan, Stan B. Kaye - Nature reviews. Cancer 2013 cited by 567

  4. Rethinking ovarian cancer: recommendations for improving outcomes

    Authors: Sebastian Vaughan, Jermaine Coward, Robert C. Bast, Andy Berchuck, Jonathan S. Berek, James D. Brenton, George Coukos, Christopher Crum, Ronny Drapkin, Dariush Etemadmoghadam, Michael Friedländer, Hani Gabra, Stan B. Kaye, Christopher J. Lord, Ernst Lengyel, Douglas A. Levine, Iain A. McNeish, Usha Menon, Gordon B. Mills, Kenneth P. Nephew, Amit M. Oza, Anil K. Sood, Euan A. Stronach, Henning Walczak, David D.L. Bowtell, Frances R. Balkwill - Nature reviews. Cancer 2011 cited by 1,507

  5. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Authors: Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye - Journal of Clinical Oncology 2010 cited by 992

  6. Ovarian cancer: strategies for overcoming resistance to chemotherapy

    Authors: Roshan Agarwal, Stan B. Kaye - Nature reviews. Cancer 2003 cited by 1,179

  7. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    Authors: Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono - Clinical Cancer Research 2014 cited by 360

  8. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

    Authors: Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg - Cancer Discovery 2017 cited by 383

  9. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

    Authors: Michele Moschetta, Angela George, Stan B. Kaye, Susana Banerjee - Annals of Oncology 2016 cited by 300

  10. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

    Authors: Louise J. Barber, Shahneen Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge S. Reis‐Filho, Víctor Moreno, Joaquı́n Mateo, L Rhoda Molife, Johann S. de Bono, Stan B. Kaye, Christopher J. Lord, Alan Ashworth - The Journal of Pathology 2012 cited by 335

  11. A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules

    Authors: Benjamin Hunter, Mitchell Chen, Prashanthi Ratnakumar, Esubalew Alemu, Andrew Logan, Kristofer Linton‐Reid, Daniel Tong, Nishanthi Senthivel, Amyn Bhamani, Susannah Bloch, Samuel V. Kemp, Laura Boddy, Sejal Jain, S. Gareeboo, Bhavin Rawal, Simon Doran, Neal Navani, Arjun Nair, Catey Bunce, Stan B. Kaye, Matthew Blackledge, Eric O. Aboagye, Anand Devaraj, Richard W. Lee - EBioMedicine 2022 cited by 46

  12. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

    Authors: Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham - The Lancet Oncology 2013 cited by 558

  13. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Authors: Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono - Journal of Clinical Oncology 2008 cited by 896

  14. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Authors: Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Friedländer, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth Lowe, James Carmichael, Bella Kaufman - Journal of Clinical Oncology 2011 cited by 474

  15. Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials

    Authors: Hendrik‐Tobias Arkenau, Jorge Barriuso, David Olmos, Joo Ern Ang, Johann S. de Bono, Ian Judson, Stan B. Kaye - Journal of Clinical Oncology 2009 cited by 207

  16. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    Authors: Tim Eisen, T. Ahmad, Keith T. Flaherty, Martin Gore, Stan B. Kaye, Richard Marais, I. Gibbens, Samuel Hackett, Maggie James, Lynn M. Schuchter, Katherine L. Nathanson, Chenjing Xia, Ronit Simantov, Brian Schwartz, Melanie Poulin-Costello, Peter J. O’Dwyer, Mark J. Ratain - British Journal of Cancer 2006 cited by 636

  17. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

    Authors: Michał Marek Hoppe, Patrick Jaynes, Joanna D. Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana GZ Lim, Brendan Pang, Sherlly Lim, Joe Yeong, Anthony N. Karnezis, Derek S. Chiu, Samuel Leung, David G. Huntsman, Anna S. Sedukhina, Ko Sato, Monique Topp, Clare L. Scott, Hyungwon Choi, Naina Patel, Robert Brown, Stan B. Kaye, Jason J. Pitt, David S.P. Tan, Anand D. Jeyasekharan - EMBO Molecular Medicine 2021 cited by 56

  18. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

    Authors: Charlotte Benson, Jeff White, Johann S. de Bono, Anne O’Donnell, Florence I. Raynaud, C. Cruickshank, Helen E. McGrath, Michael Walton, Paul Workman, Stan B. Kaye, J Cassidy, Athos Gianella-Borradori, Ian Judson, Chris Twelves - British Journal of Cancer 2006 cited by 259

  19. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    Authors: Angela George, Stan B. Kaye, Susana Banerjee - Nature Reviews Clinical Oncology 2016 cited by 158

  20. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer

    Authors: Jennifer McLachlan, Stergios Boussios, Alicia Okines, Daria Glaessgen, S. Bodlar, Ria Kalaitzaki, Allison Taylor, Susan Lalondrelle, Martin Gore, Stan B. Kaye, Susana Banerjee - Clinical Oncology 2016 cited by 87

  21. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    Authors: Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer - Journal of Clinical Oncology 2006 cited by 1,030

  22. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

    Authors: P. Vasey, Stan B. Kaye, Rachel Morrison, Chris Twelves, Peter D. Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, T. E. Hilditch, T. Murray, S S Burtles, Daniela Fraier, E. Frigerio, J Cassidy - 1999 cited by 691

  23. Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Authors: Gerhardt Attard, Joost F. Swennenhuis, David Olmos, Alison Reid, Elaine Vickers, Roger A’Hern, Rianne Levink, Frank Coumans, J.P.T. Moreira, Ruth Riisnaes, Nikhil Babu Oommen, George Hawche, Charles Jameson, Emilda Thompson, Ronald Sipkema, Craig P. Carden, Christopher Parker, David P. Dearnaley, Stan B. Kaye, Colin S. Cooper, Arturo Molina, Michael Cox, Leon W.M.M. Terstappen, Johann S. de Bono - Cancer Research 2009 cited by 532

  24. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

    Authors: H-T. Arkenau, David Olmos, Joo Ern Ang, Johann S. de Bono, Ian Judson, Stan B. Kaye - British Journal of Cancer 2008 cited by 184